226 related articles for article (PubMed ID: 21775065)
1. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.
Iqbal J; Ginsburg OM; Wijeratne TD; Howell A; Evans G; Sestak I; Narod SA
Cancer Treat Rev; 2012 Jun; 38(4):318-28. PubMed ID: 21775065
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
4. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
6. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.
Gail MH; Costantino JP; Bryant J; Croyle R; Freedman L; Helzlsouer K; Vogel V
J Natl Cancer Inst; 1999 Nov; 91(21):1829-46. PubMed ID: 10547390
[TBL] [Abstract][Full Text] [Related]
7. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of breast cancer: recommendations and rationale.
Berg AO;
Am J Nurs; 2003 May; 103(5):107, 109, 111, 113. PubMed ID: 12759615
[No Abstract] [Full Text] [Related]
9. Tamoxifen, screening and new oestrogen receptor modulators.
Neven P; Vergote I
Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):365-80. PubMed ID: 11476559
[TBL] [Abstract][Full Text] [Related]
10. The breast cancer prevention trial: should women at risk take tamoxifen?
McKeon VA
J Obstet Gynecol Neonatal Nurs; 1999; 28(6 Suppl 1):34-8. PubMed ID: 10608495
[TBL] [Abstract][Full Text] [Related]
11. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
[TBL] [Abstract][Full Text] [Related]
12. Risk-benefit profiles of women using tamoxifen for chemoprevention.
Nichols HB; DeRoo LA; Scharf DR; Sandler DP
J Natl Cancer Inst; 2015 Jan; 107(1):354. PubMed ID: 25475563
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen side effects may be attributable to other causes.
Jones J
J Natl Cancer Inst; 2001 Jan; 93(1):11-2. PubMed ID: 11136833
[No Abstract] [Full Text] [Related]
14. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
Mortimer JE; Urban JH
Oncology (Williston Park); 2003 May; 17(5):652-9; discussion 659, 662, 666 passim. PubMed ID: 12800793
[TBL] [Abstract][Full Text] [Related]
15. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
Nelson HD; Smith ME; Griffin JC; Fu R
Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749
[TBL] [Abstract][Full Text] [Related]
16. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer and duration of tamoxifen.
Prescrire Int; 2015 Sep; 24(163):220. PubMed ID: 26417636
[TBL] [Abstract][Full Text] [Related]
18. [Additional effect of SERM: mammary gland].
Kurebayashi J
Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
[TBL] [Abstract][Full Text] [Related]
19. Overview of the main outcomes in breast-cancer prevention trials.
Cuzick J; Powles T; Veronesi U; Forbes J; Edwards R; Ashley S; Boyle P
Lancet; 2003 Jan; 361(9354):296-300. PubMed ID: 12559863
[TBL] [Abstract][Full Text] [Related]
20. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis.
Bushnell CD; Goldstein LB
Neurology; 2004 Oct; 63(7):1230-3. PubMed ID: 15477543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
